Dimension Therapeutics IPO

10/22/2015

IPO

$71,500,000

We are undertaking this offering in order to access the public capital markets and to increase our liquidity. We anticipate that we will use the net proceeds received by us in this offering as follows: approximately $22 million to advance DTX101 as a treatment for hemophilia B through a Phase I/II clinical trial; approximately $22 million to advance DTX301 as a treatment for OTC deficiency through IND-enabling studies and into a Phase I/II clinical trial; approximately $12 million to advance DTX401 as a treatment for GSDIa through IND-enabling studies and into a Phase I/II clinical trial; approximately $9 million to expand our internal process development capabilities; approximately $5 million to continue to advance and to expand our research and development pipeline of our product candidates and other indications; and use the remainder for working capital and other general corporate purposes, which will include funding for the hiring of additional personnel, capital expenditures and t

Acquired or Merged

Biopharmaceutical

840 Memorial Drive
Cambridge, MA 02139
USA

Dimension Therapeutics, Inc., is a leading rare disease company focused on developing novel treatments for devastating disorders associated with the liver and based on an industry-leading, extensively validated adeno-associated virus (AAV) platform.